Anti-human papillomavirus 16 E7 T cell receptors
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsChristian S. Hinrichs, Steven A. Rosenberg
Life of this patent
Estimating the term…
Abstract
Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
Claims20
A method of producing an engineered population of human peripheral blood lymphocytes (PBLs), the method comprising:
- introducing a recombinant expression vector to an isolated population of human PBLs, wherein the recombinant expression vector comprises a nucleotide sequence encoding a T cell receptor (TCR) comprising an alpha chain complementarity determining region (CDR) 1 amino acid sequence of SEQ ID NO:
- 3, an alpha chain CDR2 amino acid sequence of SEQ ID NO:
- 4, an alpha chain CDR3 amino acid sequence of SEQ ID NO:
- 5, a beta chain CDR1 amino acid sequence of SEQ ID NO:
- 6, a beta chain CDR2 amino acid sequence of SEQ ID NO:
- 7, and a beta chain CDR3 amino acid sequence of SEQ ID NO:
- 8, and wherein the TCR has antigenic specificity for human papillomavirus (HPV) 16 E711-19.
A method of producing an engineered population of human cells, the method comprising:
- introducing a recombinant expression vector to an isolated population of human cells, wherein the recombinant expression vector comprises a nucleotide sequence encoding a polypeptide comprising a functional portion of a TCR, and wherein the functional portion has antigenic specificity for human papillomavirus (HPV) 16 E711-19 and comprises an alpha chain complementarity determining region (CDR) 1 amino acid sequence of SEQ ID NO:
- 3, an alpha chain CDR2 amino acid sequence of SEQ ID NO:
- 4, an alpha chain CDR3 amino acid sequence of SEQ ID NO:
- 5, a beta chain CDR1 amino acid sequence of SEQ ID NO:
- 6, a beta chain CDR2 amino acid sequence of SEQ ID NO:
- 7, and a beta chain CDR3 amino acid sequence of SEQ ID NO:
- 8.
A method of producing an engineered population of human cells, the method comprising:
- introducing a recombinant expression vector to an isolated population of human cells, wherein the recombinant expression vector comprises a nucleotide sequence encoding a protein having antigenic specificity for human papillomavirus (HPV) 16 E711-19 and comprising a first polypeptide chain comprising an alpha chain complementarity determining region (CDR) 1 amino acid sequence of SEQ ID NO:
- 3, an alpha chain CDR2 amino acid sequence of SEQ ID NO:
- 4, and an alpha chain CDR3 amino acid sequence of SEQ ID NO:
- 5 and a second polypeptide chain comprising a beta chain CDR1 amino acid sequence of SEQ ID NO:
- 6, a beta chain CDR2 amino acid sequence of SEQ ID NO:
- 7, and a beta chain CDR3 amino acid sequence of SEQ ID NO:
- 8.
Dependencies are inferred from the claim text.